You are here:Home-Research Areas-Other Indications-Fibrosis

Request The Product List ofFibrosis Fibrosis

Cat. No. Product Name CAS No. Information
PC-62989

Elubrixin

688763-64-6

Elubrixin (SB-656933;GSK-656933) is a potent, selective, competitive and reversible CXCR2 antagonist; inhibits CXCL1-induced CD11b up-regulation on PMNs in an in vitro whole blood assay and to be active in in vivo rodent inhalation challenge models of airway inflammation that used endotoxin and ozone to induce airway neutrophilia.

Fibrosis

Phase 2 Discontinued

PC-61128

PAT-1251

2007885-39-2

PAT-1251 (PAT 1251, PAT1251) is a potent, selective and orally bioavailable lysyl oxidase-like 2 (LOXL2) inhibitor with IC50 of 0.71 uM in human whole blood assays, with high selectivity over LOX (400-fold) and other amine oxidases; exhibits efficacy in mouse bleomycin lung fibrosis model.

Fibrosis

Phase 1 Clinical

PC-60402

GLPG-1690

1628260-79-6

GLPG-1690 (Ziritaxestat, GLPG1690) is a first-in-class, potent, competitive autotaxin inhibitor with Ki/IC50 of 15 nM/131 nM; inhibits ATX-induced LPA 18:2 production in mouse, rat, and healthy donor plasma with IC50 of 418 nM, 542 nM, and 242 nM, respectively; shows no CYP3A4 TDI and decreased hERG inhibitory activity (IC50=15 uM), and good pharmacokinetic profile for treatment idiopathic pulmonary fibrosis.

Fibrosis

Phase 2 Clinical

PC-60232

GLPG-1837

1654725-02-6

GLPG-1837 (ABBV-974) is a potent, orally available CFTR potentiator with EC50 of 3 nM and 339 nM on F508del and G551D CFTR, respectively; shows enhanced efficacy on CFTR mutants harboring Class III mutations compared to Ivacaftor.

Cystic Fibrosis

Phase 2 Clinical

PC-60231

GLPG-2222

1918143-53-9

GLPG-2222 (ABBV-2222, Galicaftor) is a novel potent and efficacious CFTR corrector with EC50 of 5 nM; is highly potent (5 nM) and efficacious in cells from multiple CF patient donors that have F508del homozygous mutation; shows potential in clinical trials in patients harboring the F508del CFTR mutation on at least one allele.

Cystic Fibrosis

Phase 2 Clinical

PC-60070

GSK-3008348 hydrochloride

1629249-40-6

GSK-3008348 hydrochloride is a novel potent, selective integrin αvβ6 antagonist for the treatment of idiopathic pulmonary fibrosis (IPF).

Cystic Fibrosis

Phase 1 Clinical

PC-60069

GSK-3008348

1629249-33-7

GSK-3008348 is a novel potent, selective integrin αvβ6 antagonist for the treatment of idiopathic pulmonary fibrosis (IPF).

Cystic Fibrosis

Phase 1 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com